Literature DB >> 1732702

Serotonergic abnormalities in the central nervous system of seizure-naive genetically epilepsy-prone rats.

J W Dailey1, P K Mishra, K H Ko, J E Penny, P C Jobe.   

Abstract

Seizure predisposition in Genetically Epilepsy-Prone Rats (GEPRs) is characterized by abnormal sensitivity to a number of seizure provoking stimuli. The GEPR model is composed of two independently derived colonies with each exhibiting a characteristic convulsive pattern. In response to a standardized sound stimulus, GEPR-3s exhibit moderate or clonic convulsions while GEPR-9s exhibit more severe tonic extensor convulsions. In order to further characterize the neurochemical abnormalities that underlie seizure predisposition in GEPRs, the current study examined serotonin concentrations in 14 discrete brain areas of controls, GEPR-3s and GEPR-9s. In all areas examined, serotonin concentrations were lower in either one or both GEPR types than in seizure resistant controls. In 6 of the 14 areas both GEPR-3s and GEPR-9s had levels significantly lower than controls. In an additional 7 areas GEPRs had serotonin concentrations of similar magnitude which were significantly lower than control when the GEPR values were combined. In cerebellum, GEPR-3s had significantly lower serotonin concentration than either controls of GEPR-9s while in the striatum, GEPR-9s had significantly lower serotonin levels than either GEPR-3s or controls. In summary, GEPRs have widespread deficits in serotonin concentration and that these abnormalities appear to contribute to the seizure predisposition that characterizes these animals.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732702     DOI: 10.1016/0024-3205(92)90340-u

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  22 in total

1.  Norepinephrine-deficient mice have increased susceptibility to seizure-inducing stimuli.

Authors:  P Szot; D Weinshenker; S S White; C A Robbins; N C Rust; P A Schwartzkroin; R D Palmiter
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

2.  Psychopathology and epilepsy: is it the chicken or the egg?

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2006 Sep-Oct       Impact factor: 7.500

Review 3.  Anxiety and epilepsy: what neurologists and epileptologists should know.

Authors:  Heidi M Munger Clary
Journal:  Curr Neurol Neurosci Rep       Date:  2014-05       Impact factor: 5.081

Review 4.  Sex dimorphism in seizure-controlling networks.

Authors:  Fillippo Sean Giorgi; Aristea S Galanopoulou; Solomon L Moshé
Journal:  Neurobiol Dis       Date:  2014-05-20       Impact factor: 5.996

Review 5.  Can Neurochemical Changes of Mood Disorders Explain the Increase Risk of Epilepsy or its Worse Seizure Control?

Authors:  Andres M Kanner
Journal:  Neurochem Res       Date:  2017-07-01       Impact factor: 3.996

6.  Cerebrospinal Fluid Levels of Monoamine Metabolites in the Epileptic Baboon.

Authors:  C Ákos Szabó; Mayuri Patel; Victor V Uteshev
Journal:  J Primatol       Date:  2015-10-14

7.  Divergent brain changes in two audiogenic rat strains: A voxel-based morphometry and diffusion tensor imaging comparison of the genetically epilepsy prone rat (GEPR-3) and the Wistar Audiogenic Rat (WAR).

Authors:  Yichien Lee; Olga C Rodriguez; Chris Albanese; Victor Rodrigues Santos; José Antônio Cortes de Oliveira; Ana Luiza Ferreira Donatti; Artur Fernandes; Norberto Garcia-Cairasco; Prosper N'Gouemo; Patrick A Forcelli
Journal:  Neurobiol Dis       Date:  2017-12-21       Impact factor: 5.996

Review 8.  Biomarkers of epileptogenesis: psychiatric comorbidities (?).

Authors:  Andres M Kanner; Andrey Mazarati; Matthias Koepp
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

Review 9.  The role of the inferior colliculus in a genetic model of audiogenic seizures.

Authors:  C E Ribak; C L Morin
Journal:  Anat Embryol (Berl)       Date:  1995-04

10.  Aspartame and seizures.

Authors:  P C Jobe; J W Dailey
Journal:  Amino Acids       Date:  1993-10       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.